CD40 and neoplasm: CD40 agonists are reported to induce anti-tumoral cytotoxic activity by TAMs; several CD40-activating antibodies and recombinant ligands are currently under clinical trials for solid tumors as single agents or in combination with chemo- and immuno-therapy, or tumor vaccines [17].